Valuation dashboard for Lipocine Inc. (LPCN) with P/E N/A, P/B 0.79, EV/EBITDA -1.23 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Analysis Summary
Trailing-twelve-month margins: gross margin 98.1%, operating margin -8.0%, net margin -7.6%.
At the current price of $2.16, LPCN has negative trailing earnings (P/E not meaningful) and an ROE of -64.75%. Market capitalisation stands at $18M.
Balance sheet quality for LPCN: current ratio of 6.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.79 |
| EV / EBITDA | -1.23 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LPCN | Lipocine Inc. | $18M | 0.79 | -64.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.16 |
| Market Cap | $18M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -64.75% |
| Return on Invested Capital | -57.74% |
| Return on Assets | -49.72% |
| Gross Margin | 98.10% |
| Operating Margin | -800.82% |
| Net Margin | -755.13% |
Related companies: ADAP · ANL · BLRX · EDSA · ERNA · GOVX · LNAI
Explore sector: Healthcare · Biotechnology
More sections of LPCN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks